Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that following a prespecified data review and recommendation by the ...

The company’s stock price has dropped to around $1.38 per share after its IPF therapy trial was stopped for safety.

The new chief medical officer of the Pulmonary Fibrosis Foundation speaks about patients in rural areas, research ...

The trial, dubbed BEACON-IPF, was assessing the biotech’s lead candidate, an oral small molecule called bexotegrast. The ...

Citi lowered the firm’s price target on Pliant Therapeutics (PLRX) to $1.50 from $4 and keeps a Neutral rating on the shares. The company ...

Cantor Fitzgerald reinstated coverage of Pliant Therapeutics (PLRX) with a Neutral rating and no price target The company is discontinuing the ...

Pliant Therapeutics shares dropped 52% to $1.64, after the company said it was discontinuing a phase 2b trial for bexotegrast in patients with idiopathic pulmonary fibrosis. The stock hit its 52-week ...

Q4 2024 Earnings Call Transcript March 3, 2025 Operator: Good day, everyone, and welcome to the Syndax Fourth Quarter and Full Year 2024 Earnings Conference Call. Today’s call is being recorded.

Pliant Therapeutics shares were halted in early morning trading after falling 25% to $2.57, after the company said it is discontinuing a phase 2b trial for bexotegrast in patients with idiopathic ...

Up to 60 new life sciences companies are set to benefit from 1.6 billion euros ($1.68 billion) that Sofinnova Partners has ...

After leaving the Big Breakfast in 1998, Denise decided to pursue a career in acting. She played Roxie Hart in the musical ...

Explore Syndax Pharmaceuticals' Q4 2024 earnings highlights, including strong Revuforj launch revenue, label expansion plans, and a $2 billion ...